Published in J Clin Pharm Ther on July 25, 2013
Micellar Enhanced Spectrofluorimetric Method for the Determination of Ponatinib in Human Plasma and Urine via Cremophor RH 40 as Sensing Agent. Int J Anal Chem (2015) 0.82
Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis and Pharmacokinetic Assessment of Ponatinib in Sprague-Dawley Rats. Oncol Ther (2016) 0.75
Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med (2012) 6.99
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell (2009) 6.97
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res (2006) 3.28
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer (2006) 2.33
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des (2010) 2.19
Recovery and relapse in anorexia and bulimia nervosa: a 7.5-year follow-up study. J Am Acad Child Adolesc Psychiatry (1999) 1.79
What predicts suicide attempts in women with eating disorders? Psychol Med (2004) 1.49
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol (2003) 1.27
Mortality in eating disorders: a descriptive study. Int J Eat Disord (2000) 1.12
Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res (2002) 1.10
Impact of severity and chronicity of parental affective illness on adaptive functioning and psychopathology in children. Arch Gen Psychiatry (1986) 1.06
Maternal expressed emotion and parental affective disorder: risk for childhood depressive disorder, substance abuse, or conduct disorder. J Psychiatr Res (1990) 1.04
Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Semin Oncol (2009) 1.03
A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol (2011) 1.03
Psychiatric disorder in adolescent offspring of parents with affective disorder in a non-referred sample. J Affect Disord (1989) 1.02
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer (2013) 0.99
A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects. Clin Cancer Res (2010) 0.97
SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage. Neurology (2005) 0.93
Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. J Clin Pharmacol (2010) 0.93
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol (2009) 0.92
The gene for schnyder's crystalline corneal dystrophy maps to human chromosome 1p34.1-p36. Hum Mol Genet (1996) 0.92
Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects. Br J Clin Pharmacol (2011) 0.92
31P Nuclear magnetic resonance spectroscopy findings in bipolar illness: a meta-analysis. Psychiatry Res (2001) 0.91
A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects. Int J Cancer (2011) 0.90
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. Ann Oncol (2012) 0.89
A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res (2004) 0.85
Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharmacol (2013) 0.84
A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor. Cancer Chemother Pharmacol (2012) 0.82
Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. Drug Metabol Personal Ther (2015) 0.81
Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects. Clin Drug Investig (2014) 0.80
Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol (2012) 0.79
Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects. Cancer Chemother Pharmacol (2014) 0.79
A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clin Drug Investig (2013) 0.78
Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. Clin Ther (2012) 0.78
Affective disorder in childhood: separating the familial component of risk from individual characteristics of children. J Affect Disord (1989) 0.76
A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults. Cancer Chemother Pharmacol (2012) 0.75
A crossover study of lecithin treatment of tardive dyskinesia. J Clin Psychiatry (1990) 0.75